1.2 OMIM# of the disease 305400.
1.3 Name of the analysed genes or DNA/chromosome segments FGD1.
OMIM# of the gene(s)
300546.
Mutational spectrum
Missense, nonsense, deletions and insertions are reported in addition to gross rearrangements. No mutational hotspots or common mutations are seen; the majority of mutations are unique within families. To the best of our knowledge, incorporating information from published articles, unpublished data and congress reports, 56 mutations have been characterised with the following mutational spectrum: 29 missense mutations, 16 frameshift mutations, 5 nonsense mutations, 3 splice site mutations, 1 in-frame deletion and 2 gross deletions. [1] [2] [3] [4] No evident genotype-phenotype correlation is apparent from comparison of patients with different mutations. 1,5
Analytical methods
Various methods have been used for detection of point mutations (denaturing high-performance liquid chromatography, sequencing, and so on). MLPA (multiplex ligation-dependent probe amplification) kits for detection of deletions/duplications of one or more exons of the FGD1 gene are commercially available.
Analytical validation
This is undertaken by analysis of independent control samples for the presumed pathogenic mutation found in affected individuals, comparison to data base entries and journal data, and testing of other affected/unaffected relatives in the family to see if the mutation segregates only with disease and avoid possible polymorphisms (mainly in cases of novel missense mutations).
1.8 Estimated frequency of the disease (incidence at birth ('birth prevalence') or population prevalence) A total of 29 molecularly proven cases have been published worldwide, 1 but the number of clinically diagnosed cases is much larger. The majority of patients published before the advent of molecular tests have not been restudied for mutations. Experience in Leuven and in Manchester (JP Fryns and J Clayton-Smith: personal communications) indicates 2-3 new patients with a proven mutation in the FGD1 gene per year, the same as for Angelman and PraderWilli syndrome, with a population prevalence of AAS probably lower or equal to 1/25 000.
1.9 If applicable, prevalence in the ethnic group of investigated persons Not applicable. Almost all individuals in whom mutations have been sought are of Caucasian origin. However, clinical experience suggests that this condition occurs in many different ethnic groups.
Diagnostic setting
Comment: Predictive testing -not applicable. As AAS is not a late onset disease and the signs are usually present in childhood, the genetic test, even in young children, are to be considered diagnostic and not predictive. Prenatal testing -see further (3.4) for considerations about the prenatal diagnosis. There are no specific therapies for AAS. Some features (hypospadias, inguinal or umbilical hernias, cryptorchidism and unusually severe craniofacial features) may need surgical intervention. Radiological and orthopaedic surveys of the cervical spine should be carried out, as compression of nerve roots may be a consequence of cervical vertebral defects (hypoplasia of the first cervical vertebra, unfused posterior arch, synostosis, anomaly of the odontoid). 9 The effect of growth hormone treatment on height gain has been reported only in preliminary studies and needs confirmation. 10 In the case of neurodevelopmental symptoms, generally mild learning problems and attention deficit and hyperactivity disorder, a neuropsychiatric opinion may be useful. 11, 12 Prognosis (please describe)
TEST CHARACTERISTICS
Due to the clinical and genetic heterogeneity, the identification of a FGD1 mutation in an AAS patient will not lead to a different prognosis, when compared with patients in whom a mutation was not found.
However, the molecular test is essential to confirm clinical diagnosis and for accurate genetic counselling of the families concerned. Management Prenatal diagnosis for pregnancies at increased risk is possible when the disease-causing mutation in the family has been identified. However, in practice, prenatal testing is unlikely to be requested frequently, as even in male patients, physical signs can be mild and the broad variability of clinical expression in an individual family makes prediction of the phenotype difficult. 13 
IF APPLICABLE, FURTHER CONSEQUENCES OF TESTING
Please assume that the result of a genetic test has no immediate medical consequences. Is there any evidence that a genetic test is nevertheless useful for the patient or his/her relatives? (Please describe).
The result of an FGD1 genetic test may have no immediate medical consequences for the affected individual and their families, but having a positive molecular genetic diagnosis will influence genetic counselling and may influence reproductive decisions. It is likely that relatives will consider genetic counselling and carrier testing to assess their own risks.
